313 related articles for article (PubMed ID: 30063847)
41. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
42. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
43. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.
Bresler SC; Min L; Rodig SJ; Walls AC; Xu S; Geng S; Hodi FS; Murphy GF; Lian CG
Lab Invest; 2017 Feb; 97(2):207-216. PubMed ID: 27918555
[TBL] [Abstract][Full Text] [Related]
44. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
[TBL] [Abstract][Full Text] [Related]
45. Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016.
Brzozowska M; Wierzba W; Śliwczyński A; Świerkowski M; Potemski P; Marczak M
Melanoma Res; 2018 Feb; 28(1):52-55. PubMed ID: 29120964
[TBL] [Abstract][Full Text] [Related]
46. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
47. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
48. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
[No Abstract] [Full Text] [Related]
49. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
[TBL] [Abstract][Full Text] [Related]
50. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Ann Oncol; 2017 Jul; 28(7):1672-1673. PubMed ID: 28407116
[No Abstract] [Full Text] [Related]
51. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
52. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
Wolchok JD; Weber JS; Maio M; Neyns B; Harmankaya K; Chin K; Cykowski L; de Pril V; Humphrey R; Lebbé C
Ann Oncol; 2013 Aug; 24(8):2174-80. PubMed ID: 23666915
[TBL] [Abstract][Full Text] [Related]
53. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
Danielli R; Fonsatti E; Calabrò L; Di Giacomo AM; Maio M
Ann N Y Acad Sci; 2012 Oct; 1270():8-12. PubMed ID: 23050811
[TBL] [Abstract][Full Text] [Related]
54. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
55. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Maio M; Grob JJ; Aamdal S; Bondarenko I; Robert C; Thomas L; Garbe C; Chiarion-Sileni V; Testori A; Chen TT; Tschaika M; Wolchok JD
J Clin Oncol; 2015 Apr; 33(10):1191-6. PubMed ID: 25713437
[TBL] [Abstract][Full Text] [Related]
56. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
[No Abstract] [Full Text] [Related]
57. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Van Allen EM; Miao D; Schilling B; Shukla SA; Blank C; Zimmer L; Sucker A; Hillen U; Foppen MHG; Goldinger SM; Utikal J; Hassel JC; Weide B; Kaehler KC; Loquai C; Mohr P; Gutzmer R; Dummer R; Gabriel S; Wu CJ; Schadendorf D; Garraway LA
Science; 2015 Oct; 350(6257):207-211. PubMed ID: 26359337
[TBL] [Abstract][Full Text] [Related]
58. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
59. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Lotem M; Merims S; Frank S; Ospovat I; Peretz T
Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
[TBL] [Abstract][Full Text] [Related]
60. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients.
Jensen C; Madsen DH; Hansen M; Schmidt H; Svane IM; Karsdal MA; Willumsen N
J Immunother Cancer; 2018 Dec; 6(1):152. PubMed ID: 30567561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]